Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuing Care01:25

Continuing Care

1.5K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

330
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
330
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

641
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
641
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

237
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

25
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
25
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

596
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
596

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mesial temporal shape asymmetry as a neuro-imaging correlate of epilepsy in mild cognitive impairment and dementia.

Brain communications·2026
Same author

The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol.

Contemporary clinical trials communications·2026
Same author

Co-morbid seizures in frontotemporal dementia: MRI and PET correlations.

Epilepsy & behavior reports·2026
Same author

Using the Word <i>Want</i> in Health Care May Leave Patients Wanting.

Journal of palliative medicine·2025
Same author

Co-morbid seizures in frontotemporal dementia: What do they tell us?

Epilepsy research·2025
Same author

Development of the Movement Disorders Interpretation Bias Scale and psychometric evaluation in adults with Huntington's disease.

Parkinsonism & related disorders·2025

Related Experiment Video

Updated: Aug 12, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K

Primary Palliative Care in Huntington's Disease.

Madaline B Harrison1, Dana L Morrissey1, W Alex Dalrymple1

  • 1Department of Neurology University of Virginia Charlottesville Virginia USA.

Movement Disorders Clinical Practice
|January 26, 2023
PubMed
Summary
This summary is machine-generated.

Integrating palliative care into Huntington

Keywords:
Huntington's diseaseinterdisciplinary careneurodegenerative diseasepalliative care

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

447

Related Experiment Videos

Last Updated: Aug 12, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
02:22

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

447

Area of Science:

  • Neurology
  • Palliative Medicine
  • Healthcare Management

Background:

  • Palliative care, including goals of care communication and advance care planning (ACP), can improve care for Huntington's disease (HD) patients.
  • A pilot program was developed to integrate primary palliative care with interdisciplinary HD care.

Purpose of the Study:

  • Train HD team members to facilitate goals of care and ACP conversations across all HD stages.
  • Develop patient-centered care planning materials focusing on quality of life.
  • Adapt clinic workflow for integrating goals of care and ACP discussions.

Main Methods:

  • Defined planning domains beyond end-of-life issues.
  • Created a patient and family guide for HD advance care planning.
  • Conducted VitalTalk communication training and modified clinic workflow, including EMR template development.

Main Results:

  • Post-training, team members' confidence in discussing serious news increased from 12.5% to 50%.
  • Confidence in managing difficult conversations rose from 25% to 62.5%.
  • Advance care planning discussions occurred in 30.6% of clinic visits, up from 12.5%.

Conclusions:

  • Delivering primary palliative care within an interdisciplinary HD clinic is feasible.
  • Integrating palliative care into HD specialty care necessitates further training and operational adjustments.